Systemic and Intra-Nodal Activation of NK Cells After Rituximab Monotherapy for Follicular Lymphoma

Monika Enqvist1, Benedikt Jacobs2,3,4†, Henna R. Junlén5,6†, Marie Schaffer1, Christopher M. Melén6,7, Danielle Friberg7, Björn Engelbrekt Wahlin5,6† and Karl-Johan Malmberg1,2,3,5,6*

† These authors have contributed equally to this work

INTRODUCTION

Follicular Lymphoma (FL) is the second most common non-Hodgkin’s lymphoma and accounts for 20% of all lymphomas. Most patients respond well to series of treatment strategies, but the relapse rate is high and the disease is in the majority of cases incurable (1). Since the initial demonstration that monotherapy with rituximab, an antibody recognizing the CD20 antigen expressed on mature...
B cells, could improve the survival in FL (2–4), immunotherapy has become a corner stone in the therapy of most B cell lymphomas. One of the major mechanisms of action for rituximab is antibody-dependent cellular cytotoxicity (ADCC), which is mediated by natural killer (NK) cells and/or macrophages (5, 6). NK cells perform ADCC through engagement of an FcγRIIIA/CD16 receptor to the Fc-part of antibodies bound to the target cell. This process is known to trigger strong NK cell activation through different pathways including release of cytotoxic granules and pro-inflammatory cytokines as IFNγ (7).

The involvement of NK cells in the clinical effects of rituximab is indirectly supported by the findings that NK cells are rapidly cleared from the circulation after therapy with rituximab (8), and the correlation with polymorphisms in the FcγRIIIA gene (5, 9, 10). In many clinical studies it is challenging to determine the isolated immunological response to rituximab because of different treatment combinations. In one study the outcome in non-Hodgkin’s lymphoma patients correlated with expansion of NK cells and increased ADCC after the patients received IL-2 in addition to rituximab therapy (11). Functional in vitro studies have shown that rituximab activates a broad range of NK cell subsets, independently of their expression of self-HLA binding inhibitory KIRs, thus overriding the need for education (12). On the other hand, it has been reported that tumor cells can increase HLA class I expression in response to IFNγ stimulation and thereby escape NK cell killing. However, the in vivo dynamics of the NK cell repertoire, both systemically and in the lymph node, during monotherapy with rituximab is largely unexplored. In this study, we examined the immune repertoire in sequential biopsies of the affected lymph node and in peripheral blood in FL patients receiving monotherapy with rituximab. Our results point to a diversified immunological response where some patients display a pronounced up-regulation of Ki67 associated with a temporary drop in NK cell function. The kinetics of the response was linked to the presence of adaptive NK cell subsets in the patient and may hold clues to clinical responsiveness to antibody therapy.

RESULTS

NK Cell Frequency and Phenotype in Lymph Node and Peripheral Blood

Eight patients diagnosed with follicular lymphoma were included in the study (Table 1). All patients were previously untreated and received in total four doses of rituximab (Figure 1A). We first established multi-color flow cytometry panels to monitor the immune subset composition in fine needle biopsies from tumor lymph nodes (LN) and peripheral blood (PB) before each treatment cycle at a weekly interval. The biopsy sample collection continued until the tumor lymph nodes were too small to access. The NK cell frequency in LN samples were consistently low compared to frequencies seen in PB (Figures 1B,C), with patients showing both increasing and decreasing trends over time. However, the relative LN-NK frequency of total CD45+ and CD19−CD20− cells were similar to what we found in tonsil samples from healthy donors. In agreement with earlier studies (13), we found a decrease of NK cells in peripheral blood 7 days after rituximab treatment started manifested as lower frequencies and lower absolute counts (Figures 1D,E).

Next, we determined the expression of activating and inhibitory receptors, including killer cell immunoglobulin-like receptors (KIR), NKG2A and NKG2C, effector molecules and maturation markers on intra-nodal and peripheral blood NK cells (Figure 2). In line with previous findings (14, 15), we observed a dominance of CD56bright NK cells in tonsils from healthy donors (average 56%, range 37–71%). Tonsils are widely used as a control in FL (16, 17), albeit they represent a more inflamed tissue compared to normal lymph nodes from healthy individuals. Tonsils contain more differentiated T cells and are more similar to FL tumors in terms of immune cell composition and differentiation states (18). Indeed, compared to normal tonsils, LN-NK cells in FL patients showed an intermediate phenotype, with an average of 71% CD56dim cells. This intermediate state was also reflected in the relative expression of CD57, KIRs and CD16 on CD56dim NK cells when compared to the same subset in tonsil-derived NK cells and PB-NK cells (Figure 2B). Although we cannot formally exclude that ILCs contributed to the relative composition in CD56+CD3- cells in LN and tonsils, ILCs typically lack CD16, KIR and NKG2A. Furthermore, LN-NK cells expressed lower levels of the effector molecules Granzyme A/B and Perforin than PB-NK cells. The maturation and cytotoxic phenotypes of both LN-NK and PB-NK cells were highly stable over time with the exception of increased Granzyme B in LN-NK after treatment and a small increase of NKG2A+ cells in PB-NK cells 7 days after the first rituximab administration. We can not formally exclude that dynamics in ILCs contributed to the

Rituximab Therapy Is Associated With a Rapid Induction of Ki67 Expression

To further dissect the NK cell response to rituximab treatment in the patients we stained for the intracellular marker Ki67, which is found in recently divided or cycling cells. Before treatment the Ki67 level in the patients’ LN-NK cells was higher than tonsil control NK cells, while PB-NK cells had comparable level to what was seen in healthy controls (Figures 3A,B). Seven days after treatment start, we found a consistent increase of Ki67 expression in both LN-NK and PB-NK. After 14 days the Ki67 expression had, in most instances, declined to baseline levels and remained low during the subsequent administration of rituximab. This indicates the observed induction of Ki67 on NK cells in the patients was a direct consequence of the rituximab treatment but that this response was limited to the first administration. The Ki67+ NK cells at day 7 expressed relatively higher levels of CD16, CD57, KIRs, NKG2C, Perforin and Granzyme A than Ki67+ NK cells at baseline, suggesting that NK cell activation was accompanied with cellular differentiation (Figure 3C).

Temporary Loss of NK Cell Function After Rituximab Treatment

To assess whether the repertoire dynamics was associated with changes in NK cell function, we monitored degranulation (CD107a) and cytokine production (IFNγ) in peripheral blood...
TABLE 1 | Patient characteristics.

| ID     | Age  | Diagnosis | Stage | FLIPI | Treatment indication            | Response* | Response** | Months in remission | Subsequent treatments |
|--------|------|-----------|-------|-------|----------------------------------|-----------|------------|--------------------|----------------------|
| RITFL01 | 60–65| FL low grade | IV    | Int   | High tumor burden, B symptoms   | PR   | CR         | 5                  | R-Idelalisib, R-Bendamustine |
| RITFL02 | 30–35| FL 3A      | III   | Low   | Pain in enlarged lymph nodes     | CR   | CR         | 68+                |                      |
| RITFL03 | 35–40| FL 2       | IV    | High  | High tumor burden, B symptoms   | PO   |            |                    |                      |
| RITFL04 | 65–70| FL 2       | IV    | High  | Progressive disease              | PR   | CR         | 61+                |                      |
| RITFL05 | 40–45| FL 2       | III   | Int   | Progressive disease, high tumor burden | PR   | PR         | 17                 | R                    |
| RITFL06 | 70–75| FL 2       | III   | High  | Progressive/bulky disease        | PR   | PR         | 16                 | R-Bendamustine       |
| RITFL07 | 70–75| FL low grade | IV   | High  | Progressive disease              | PR   | CR         | 57+                |                      |
| RITFL08 | 80–85| FL low grade | III  | Low   | Progressive disease              | PR   | CR         | 10                 | R-Bendamustine       |

FLIPI, Follicular Lymphoma International Prognostic Index; PR, partial remission; CR, complete remission; R, rituximab; CHOP, cyclophosphamide, doxorubicine, vincristine and prednisolon; BEAM, carmustine, etoposide, cytarabine and melphalan; ASCT, autologous stem cell transplantation. *After 10 weeks (1 × 4 rituximab); **After 22 weeks (2 × 4 rituximab); + Ongoing remission; # Alive at latest follow up.

FIGURE 1 | Decreased NK cell frequency and cell count in peripheral blood after treatment. (A) Outline of treatment and sample collection in the patients. (B) Representative flow cytometry staining of CD56+CD3− NK cells in tumor lymph node and peripheral blood. Frequency CD56+CD3− NK cells of total tumor negative and CD45+ cells in (C) lymph node (LN) and (D) peripheral blood (PB). (E) NK cell counts in PB. Patients N = 8, healthy controls N = 10. Differences were assessed using the Wilcoxon signed rank test for comparisons of matched samples within patients or Mann-Whitney t-test for comparisons between healthy controls and patients, *p < 0.05.

NK cells after stimulation with 721.221 cells coated with rituximab (Figure 4A). We found a reduction in multifunctional responses, primarily due to a significantly decreased IFNγ-production at day 7 after systemic rituximab treatment in some but not all patients (Figures 4B, C). NK cell function gradually returned to normal over the course of 2–3 weeks.
FIGURE 2 | Tumor lymph node NK cells have an intermediate differentiated phenotype compared to tonsil NK cells and peripheral blood NK cells. (A) Example of flow cytometry staining of NK cells in tumor lymph node and peripheral blood. (B) Frequency CD56<sup>dim</sup> NK cells of total CD56<sup>+</sup> cells, and frequency NKG2A<sup>+</sup>, CD57<sup>+</sup>, and Granzyme A.
Notably, three of the patients showed an opposite trend with a more stable or even increased NK cell function at day 7 and beyond. The relative loss of IFNγ-production appeared to be most prominent in patients that had a relatively higher induction of Ki67+ NK cells at day 7 (Figure 4D).

Approximately 30–40% of CMV seropositive donors harbor expansion of adaptive NK cells expressing high levels of NKG2C and CD57 (19, 20). This specific NK cell subset displays epigenetic imprinting of the IFN promoter and responds strongly to antibody-coated targets (21–23). Although the number of patients in the study is small, stratifying the patients into two groups based on presence of NKG2C expansions above 5% revealed a trend toward a more stable IFNγ-production over time in patients with adaptive NKG2C+ cells (Figures 4E,F).

**Rituximab Pretreatment Reduces Antibody-Dependent NK Cell Functions in vitro**

To further study the effect of rituximab on NK cell proliferation and ADCC function PBMCs from healthy donors were cultured with 1 ng/ml IL-15 to induce proliferation, in the presence or absence of a short term (48 h) stimulation with rituximab (10 µg/ml). Rituximab pretreatment resulted in a small but significant increase in the proportion of rapidly cycling NK cells at day 6 (Figures 5A,B). Under these experimental conditions, adaptive NKG2C+ NK cells proliferated less than conventional NK cells (Figure 5C). In agreement with the *ex vivo* data, degranulation and cytokine production in response to antibody-coated target cells were reduced in rapidly proliferating NK cells (Figure 5D) and in cells with prior exposure to rituximab (Figure 5E). In line with their low-grade proliferation, NKG2C+ NK cells displayed higher functional responses after rituximab stimulation (Figure 5F). Hence, at the repertoire level, IFNγ production was more stable in donors with pre-existing CMV-driven expansions of NKG2C+ NK cells (Figure 5G).

**DISCUSSION**

NK cells are believed to contribute to the successful eradication of malignant B cells following rituximab therapy, but the mechanism for this is not well-defined. In this study we performed a detailed analysis of the dynamics including functional and phenotypical characteristics of the NK cell response to rituximab treated FL-patients. NK cells in tumor-affected lymph nodes had an immature phenotype, albeit more differentiated than tonsil NK cells used as negative control. Both lymph node and peripheral blood NK cells showed signs of activation/proliferation during the first week after initiation of rituximab treatment. These phenotypic imprints were linked to a temporary loss in functionality. These early dynamic events may hold clues to the role of NK cell-mediated ADCC in the clinical response to therapeutic monoclonal antibodies.

There are surprisingly few studies assessing the NK cell compartment in primary human lymph nodes and tonsils and to our knowledge there is none describing dynamic events following immunomodulatory therapy. Healthy human tonsils and lymph nodes were found to contain 5 and 0.4% NK cells, respectively (15). It was previously reported that 95% of lymph node NK cells are CD56bright (14). We confirm these low numbers of NK cells in lymphoid tissues although NK cell frequencies were similarly low in tumor lymph node biopsies and healthy control tonsils. However, the tumor-affected lymph nodes contained relatively higher numbers of CD56dim NK cells. In addition, several surface receptors associated with a mature cytotoxic phenotype, including CD16, CD57, and KIRs, were expressed at a higher level in tumor-affected lymph nodes compared to tonsil controls. This could reflect an ongoing immunological response to the tumor cell growth.

Besides cytotoxic effector functions, activated NK cells can produce high levels of cytokines, which may in turn lead to further activation of several immune cell types including T cells (8). Previous studies have shown that cytotoxic lymphocytes predominantly reside at the periphery of follicles and in the interfollicular areas close to T cells (24). In this compartment, the interplay with T cells secreting IL-2 leads to NK cell-mediated release of IFNγ (14). IFNγ release can lead to up-regulation of HLA molecules and thereby affect the T cell response, it also stimulates macrophages to increased phagocytosis in addition to lymphocyte recruitment and a prolonged activation (25). An increased CD8+ T-cell infiltrate correlates to better prognosis in FL (26) although chronic stimulation of intra-nodal T cells may also lead to T-cell exhaustion in FL patients (27, 28).

Release of pleiotropic cytokines by LN-NK cells in response to rituximab can furthermore influence the local immune response through increased expression of the high-affinity Fcγ receptors CD64 on granulocytes (29) and through M1-polarization of macrophages (30). *In vitro* studies have suggested rituximab to induce cytotoxic T cell response after promoting phagocytosis and dendritic cell cross-presentation (31). Indeed, anti-CD20 therapy led to a long-lasting protection against CD20+ tumor cells in mice by inducing a CD8+ and CD4+ dependent cellular immune response (32). Similarly, vaccination with autologous DC following low dose of intra-nodal rituximab was associated with CR and induction of systemic immunity in patients with FL (33).

We noted a rapid but temporary decline in NK cell numbers in the periphery after rituximab therapy. Unfortunately it was not possible to trace the fate of these cells and determine whether they egressed from peripheral blood to reach other compartments. We did not detect any reciprocal increase in NK cell frequencies in the lymph node. It is possible that we missed the kinetics of these
Increased frequency of Ki67+ CD56dim NK cells after rituximab treatment. (A) Representative example of flow cytometry staining and (B) summary showing frequency Ki67+ CD56dim NK cells before (light blue) and after (dark blue) treatment in tumor lymph node and peripheral blood. (C) Expression of NKG2A, CD57, KIRs, NKG2C, CD16, granzyme A/B and perforin on Ki67 positive and negative CD56dim NK cells from peripheral blood. Healthy controls are shown in white. Patients N = 8, healthy controls N = 10. Differences were assessed using the Wilcoxon signed rank test for comparisons of matched samples within patients or Mann-Whitney U-test for comparisons between healthy controls and patients, *p < 0.05 and **p < 0.01.
FIGURE 4 | Altered function of peripheral blood CD56dim NK cells after treatment. (A) Flow cytometry staining of CD107a and IFNγ on peripheral blood NK cells from patients, with or without tumor cell and rituximab stimulation. (B) Relative frequency of CD107a and IFNγ positive CD56dim NK cells after stimulation with 721.221 cells coated with rituximab, in patients (n = 7) before (Day 0) and after (Day 7) treatment. (C) CD56dim NK cell IFNγ response to 721.221 cells coated with rituximab in the individual patients before and during the first 3 weeks after therapy (N = 7). (D) Correlation of relative IFNγ response to relative Ki67 expression (day 7 compared to day 0). (E) Flow cytometry staining showing NKG2C and CD57 expression in the individual patients at Day 0. (F) Relative IFNγ production at day 7 in patients with less or more than 5% NKG2C+ CD56dim NK cells.

early events by sampling the lymph node weekly. However, Ki67 expression was induced on both PBL-NK and LN-NK 1 week after the first dose of rituximab. The NK cell number in lymph node biopsies was too low to allow further subset analysis of the emerging Ki67+ NK cell population. In PBL, Ki67+ NK cells had a slightly more differentiated phenotype at day 7 than day 0 and compared to Ki67+ NK cells in healthy controls. These data suggest that rituximab triggers a rapid proliferative NK
cell response associated with cellular differentiation. Intriguingly, the phenotypic imprints were normalized and had returned to baseline at day 14 in most patients. Also, the NK cell repertoires were stable following the 2nd to 4th treatment cycle. In one of the patients we noted a slower kinetics with a peak in Ki67 expression occurring at day 14. This slow kinetics correlated with a delayed clinical response to the treatment in this particular patient.

In the majority of the patients we observed an attenuated response to in vitro stimulation with rituximab-coated target cells 1 week after the first treatment cycle. This drop in functionality coincided in time with the increased expression of Ki67. In
fact, we noted a positive correlation between the degree of Ki67 upregulation at day 7 and loss of IFNγ production in vitro. Ki67 may reflect a more general NK cell activation but it is also possible that these cells have undergone recent cell division. Onset of cell division and the associated changes in metabolism may reprogram the functionality of the cell leading to decreased cytokine production. Therefore, it is tempting to speculate that the decreased in vitro functionality observed at day 7 represent a form of functional exhaustion following the primary in vivo response to systemic rituximab therapy. If this is the case, variation in the in vitro response may hold clues to the efficacy of the therapy. Supporting this notion, one in vitro study reported hyporesponsiveness in NK cells following pre-treatment with rituximab (34). In this short-term model, exposure to rituximab primarily affected cytotoxicity while no effect was seen on the IFNγ production. In contrast, our data showed altered cytokine production while the degranulation toward rituximab-coated target cells was less affected. Furthermore, we found stable or increased levels of the cytotoxic effector molecules granzyme A/B and perforin after treatment, suggesting the ability to perform cellular cytotoxicity remained intact. In a few patients we observed an opposite trend with a stable or even increased functional response at day 7. Intriguingly, these patients had evidence of a weaker systemic imprint of rituximab therapy and harbored significant adaptive NK cell populations determined by the expression of NKG2C and CD57. Adaptive NK cells have increased capacity to produce IFNγ in response to antibody-coated target cells due to epigenetic changes in the IFNγ promoter (21–23, 35). Patients having NKG2C+ NK cells could theoretically thus already from the start be better equipped for cytokine production in response to rituximab treatment thereby explaining their functional stability over time. Although these data are based on few patients, this notion was supported by an in vitro model for rituximab-induced proliferation where we noted a profound loss of function in proliferating NK cells that was less dramatic in donors harboring adaptive NK cell expansions, linked to the poor proliferative response and functional loss noted in these patients. The primary objective of our study was to explore longitudinal phenotypic and functional imprints of rituximab monotherapy. The study was underpowered to link immune variation to clinical outcomes. Nevertheless, the diversified response observed in this study suggest that probing dynamic systemic and local immune imprints may hold utility as a metrics of the patients’ ability to respond to therapy and thereby a predictor treatment efficacy.

MATERIALS AND METHODS

Patients

This study was approved by the Regional Ethical Review Board in Stockholm, Sweden. Fine needle biopsies from tumor lymph nodes and peripheral blood were collected after informed consent from 8 patients diagnosed with follicular lymphoma. Samples were obtained before treatment, and 7, 14, and 21 days after the treatment with rituximab started. Collection of the fine needle biopsies ended earlier if the tumor lymph nodes were too small to access. Age matched healthy control cells were collected from buffy coats and tonsils. The cells from peripheral blood and tonsils were enriched by density gradient (Ficoll-Hypaque; GE Healthcare) and PBMCs, cells from tonsils and fine needle biopsy cells were cryopreserved in 90% FCS and 10% DMSO for later analysis. CMV serology was determined using an ELISA-based assay on plasma obtained during sample preparation. Purified nuclear antigen (AD 169) was used and the cut-off level for seropositivity was an absorbance of >0.2 dilution of 1/100.

Antibodies and Flow Cytometry

The following conjugated monoclonal antibodies (mAbs) were used: Ki67 (clone: B56), CD14 (M@P9), CD57 (NK-1), Granzyme B (GB11), CD107a (H4A3), IFNγ (B27), CD19 (HB19) from BD Biosciences, NKG2A (z199), CD3 (UCHT1), CD56 (N901), KIR2DL2/3/S2 (GL183), KIR2DL1/S1 (EB6), CD19 (33-119) from Beckman Coulter, CD16 (3G8), CD20 (2H7), CD45 (H130), Granzyme A (CB9), KIR3DL1 (dx9) from BioLegend, Perforin (dG9), κ-chain (TB28-2), λ-chain (TB28-2), Granzyme K (G3H69) from eBioscience, KIR2D-biotin (NKVFS1), KIR3DL1/2-biotin (5.133), KIR2DL1 (REA284) from Miltenyi, NKG2C (134591) and 2DL3 (180701) from R&D Systems. For phenotypic analysis of cells, PBMCs and cells from fine needle biopsies were incubated at 4°C in the dark with surface mAbs, washed with PBS and additionally stained with Streptavidin-Qdot655 (Invitrogen) and Live/Dead fixable aqua dead cell stain (Invitrogen). After wash with PBS the cells were fixed and permeabilized with fix/perm kit (eBiosciences), washed and stained with intracellular mAbs. Data were acquired in FACSDiva software on a BD LSRFortessa equipped with a 488-nm laser, a 633-nm laser, a 405-nm laser, and a 562-nm laser. Acquired data were analyzed in FlowJo 9.8 (Tree Star).

Functional Flow Cytometry Assay

PBMCs were rested overnight at 37°C and 5% CO2 in RPMI 1640 supplemented with 10% FCS and 5 mM L-glutamine. Cells were mixed with 721.221 target cells at a 10:1 ratio and incubated 6 h with or without rituximab (1 μg/ml). CD107a antibody, GolgiStop (1:1,500, BD Biosciences) and GolgiPlug (1:1,000, BD Biosciences) were added after 1 h of co-incubation. At the end of the assay additional CD107a antibody was added together with the surface mAbs, following staining procedure as described above.

In vitro Experiments

PBMCs were isolated from buffy coats obtained from healthy blood donors from the Oslo University Hospital Blood bank (donor informed consent included). Cells were labeled with CellTrace™ Violet or CFSE™ dye for cell proliferation analysis according to the kit’s instructions (Molecular Probes). CTV-/CFSE -labeled PBMCs were culture in RPMI 1640 media (Sigma) with antibiotics (penicillin/ streptomycin; Sigma) and 10% human, heat-inactivated AB serum (Trina Bioreaktives) plus 1 ng/ml IL-15 (Miltenyi Biotec) for 6 days at 37°C with or without 10 μg/ml rituximab (Roche) for the first 48 h. On day 2 and 4 the medium was replaced with fresh medium and IL-15. After 6 days cells were analyzed for
the number of dividing NK cells by flow cytometry. In addition, cells were mixed with 721.221 target cells, which have been labeled with or without rituximab, at a 1:1 ratio and incubated for 4 h at 37°C. CD107a antibodies were added directly, whereas GolgiStop (1:1,500, BD Bioscience) and GolgiPlug (1:1,000, BD Bioscience) were added after 1 h of co-incubation. At the end of the culture, cells were stained with surface and intracellular mAbs, following staining procedure as describe above.

Statistical Analysis
For comparisons Wilcoxon matched test or for unpaired groups Mann-Whitney test was used. p-values: * < 0.05, ** < 0.01, *** < 0.001, **** < 0.0001. Analysis was performed using GraphPad Prism 6 software.

DATA AVAILABILITY
All data generated and/or analyzed during the current study are available on reasonable request (kalle.malmberg@ki.se).

ETHICS STATEMENT
The studies involving human participants were reviewed and approved by the regional ethics committee in Stockholm, Sweden. The regional ethics committee in Oslo, Norway. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS
ME and BJ conducted experiments and analyzed the data. MS performed HLA and KIR typing. HJ, CM, and DF contributed with clinical samples and biobanking. ME, BW, and K-JM designed research and wrote the manuscript. K-JM is a scientific advisor and consultant at Fate Therapeutics.

FUNDING
This work was supported by grants from the Swedish Research Council, the Swedish Children's Cancer Society, the Swedish Cancer Society, the Tobias Foundation, the Karolinska Institutet, the Wenner-Gren Foundation, the Norwegian Cancer Society, the Norwegian Research Council, the South-Eastern Norway Regional Health Authority and the KG Jebsen Center for Cancer Immunotherapy, SP was supported by BB/N01524X/1 from the BBSRC and BJ was funded by a Mildred Scheel postdoctoral scholarship from the Dr. Mildred Scheel Foundation for Cancer Research of the German Cancer Aid Organization.

REFERENCES
1. Kritharis A, Sharma J, Evans AM. Current therapeutic strategies and new treatment paradigms for follicular lymphoma. Cancer Treat Res. (2015) 165:197–226. doi: 10.1007/978-3-319-13150-4_8
2. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. (2002) 346:3235–42. doi: 10.1056/NEJMoa011795
3. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, White CA, Liles TM, Royston I, et al. IDEC-C2B8: results of a phase 1 multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol. (1997) 15:3266–74. doi: 10.1200/JCO.1997.15.10.3266
4. McCaughrin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. (1998) 16:2825–33. doi: 10.1200/JCO.1998.16.8.2825
5. Dall’Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FcGR3A polymorphism on the concentration-effect relationship. Cancer Res. (2004) 64:4664–9. doi: 10.1158/0008-5472.CAN-03-2862
6. Uchida J, Hamaguchi Y, Oliver JA, Bodkin DC, Haas KM, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med. (2004) 199:1659–69. doi: 10.1084/jem.20040119
7. Bryceson YT, March ME, Ljunggren HG, Long EO. Activation, co-activation, and costimulation of resting human natural killer cells. Immunol Rev. (2006) 214:73–91. doi: 10.1111/j.1600-065X.2006.00457.x
8. Bowles JA, Weiner GJ. CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J Immunol Methods. (2005) 304:88–99. doi: 10.1016/j.jim.2005.06.018
9. Veeramani S, Wang SY, Dahle C, Blackwell S, Jacobs L, Knutson T, et al. Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. Blood. (2011) 118:3347–9. doi: 10.1182/blood-2011-05-351411
10. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. (2003) 21:3940–7. doi: 10.1200/JCO.2003.03.013
11. Gluck WL, Hurst D, Yuen A, Levine AM, Dayton MA, Gockerman JP, et al. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res. (2004) 10:2253–64. doi: 10.1158/1078-0432.CCR-1087-3
12. Du J, Lopez-Verges S, Pitcher BN, Johnson J, Jung SH, Zhou L, et al. CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol Res. (2014) 2:878–89. doi: 10.1158/2326-6066.CIR-13-0158
13. Cox MC, Battella S, La Scaleia R, Pelliccia S, Di Napoli A, Porzia A, et al. Tumor-associated and immunonochemotherapy-dependent long-term alterations of the peripheral blood NK cell compartment in DLBCL patients. Oncoimmunology. (2015) 4:e990773. doi: 10.4161/2162402X.2014.990773
14. Feinberg TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, Colonna M, et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood. (2003) 101:3052–7. doi: 10.1182/blood-2002-09-2876
15. Ferlazzo G, Thomas D, Lin SL, Goodman K, Morandi B, Muller WA, et al. The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol. (2004) 172:1455–62. doi: 10.4049/jimmunol.172.3.1455
16. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. (2004) 351:2159–69. doi: 10.1056/NEJMoa041869
17. Jofesfson SE, Huse K, Kolstad A, Beiske K, Pende D, Steen CB, et al. T cells expressing checkpoint receptor TIGIT are enriched in follicular lymphoma tumors and characterized by reversible suppression...
of T-cell receptor signaling. Clin Cancer Res. (2018) 24:870–81. doi: 10.1185/1078-0432.CCR-17-2337

18. Hilchey SP, Rosenberg AF, Hyrien O, Secor-Socha S, Cochran MR, Brady MT, et al. Follicular lymphoma tumor-infiltrating T-helper (TH) cells have the same polyfunctional potential as normal nodal TH cells despite skewed differentiation. Blood. (2011) 118:3591–602. doi: 10.1182/blood-2011-03-340646

19. Guma M, Angulo A, Vilches C, Gomez-Lozano N, Malats N, Lopez-Botet M. Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood. (2004) 104:3664–71. doi: 10.1182/blood-2004-05-2058

20. Lopez-Verges S, Milush JM, Schwartz BS, Pando MJ, Jarjoura J, York VA, et al. Expansion of a unique CD57(+)NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc Natl Acad Sci U.S.A. (2011) 108:14725–32. doi: 10.1073/pnas.1110900108

21. Lee J, Zhang T, Hwang I, Kim A, Nitschke L, Kim M, et al. Epigenetic modification and antibody-dependent expansion of memory-like NK cells in human cytomegalovirus-infected individuals. Immunity. (2015) 42:431–42. doi: 10.1016/j.immuni.2015.02.013

22. Luetke-Eversloh M, Hammer Q, Durek P, Nordstrom K, Gasparoni G, Pink M, et al. Human cytomegalovirus drives epigenetic imprinting of the IFNG locus in NKG2Chi natural killer cells. PLoS Pathog. (2014) 10:e1004441. doi: 10.1371/journal.ppat.1004441

23. Schlums H, Cichocki F, Tesi B, Theorell J, Beziat V, Holmes TD, et al. Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function. Immunity. (2015) 42:443–56. doi: 10.1016/j.immuni.2015.02.008

24. Perambakam S, Naresh K, Nerurkar A, Nadkarni J. Intra-tumoral cytolytic cells pattern of distribution in B-cell non Hodgkin’s lymphoma. Pathol Oncol Res. (2000) 6:114–7. doi: 10.1007/BF03032360

25. Schoenborn JR, Wilson CB. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol. (2007) 96:41–101. doi: 10.1016/S0065-2776(07)96002-2

26. Alvaro T, Lejeune M, Salgado MT, Lopez C, Jaen J, Bosch R, et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol. (2006) 24:5350–7. doi: 10.1200/JCO.2006.06.4766

27. Yang ZZ, Grote DM, Ziesmer SC, Niki T, Hirashima M, Novak AJ, et al. IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J Clin Invest. (2012) 122:1271–82. doi: 10.1172/JCI59806

28. Ramsay AG, Clear AJ, Kelly G, Fatah R, Matthews J, Macdougall F, et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood. (2009) 114:4713–20. doi: 10.1182/blood-2009-04-217687

29. Hoffmeyer F, Witte K, Schmidt RE. The high-affinity Fc gamma RI on PMN: regulation of expression and signal transduction. Immunology. (1997) 92:544–52. doi: 10.1046/j.1365-2567.1997.00381.x

30. Haabeth OA, Lokvik KB, Hammarstrom C, Donaldson IM, Haraldsen G, Bogen B, et al. Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun. (2011) 2:240. doi: 10.1038/ncomms1239

31. Selenko N, Maedic O, Drexler S, Berer A, Jager U, Knapp W, et al. CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells. Leukemia. (2001) 15:1619–26. doi: 10.1038/sj.leu.2402226

32. Abes R, Gelise E, Fridman WH, Tellaud JL. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood. (2010) 116:926–34. doi: 10.1182/blood-2009-10-248609

33. Kolstad A, Kumari S, Walczak M, Madsbu U, Hagtvedt T, Borsrud TV, et al. Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma. Blood. (2015) 125:82–9. doi: 10.1182/blood-2014-07-592162

34. Capuano C, Romanelli M, Pighi C, Cimino G, Rago A, Molfetta R, et al. Anti-CD20 Therapy acts via FcgammaRIIA to diminish antibody-dependent and correlated regression of disseminated follicular lymphoma. Blood. (2015) 116:926–34. doi: 10.1182/blood-2009-10-248609

35. Foley B, Cooley S, Verneris MR, Pitt M, Curtsinger J, Luo X, et al. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood. (2012) 119:2665–74. doi: 10.1182/blood-2011-10-386995

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Enqvist, Jacobs, Junlén, Schaffer, Melén, Friberg, Wahlin and Malmberg. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.